Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3162296 | 0.99 | KMT2A (0.55) | KMT2ACASP3EPHX2MDM4TP53 | |
| Bromide SCHEMBL15640173 | 0.88 | KMT2A (0.53) | KMT2ACASP3EPHX2TLR2 | |
| Hydrochloric Acid SCHEMBL2524994 | 0.88 | KMT2A (0.53) | KMT2ACASP3EPHX2TLR2 | |
| SCHEMBL992905 | 0.86 | TLR2 (0.54) | KMT2ACASP3EPHX2TLR2 | |
| Bromide SCHEMBL19100909 | 0.85 | TLR2 (0.54) | KMT2ACASP3EPHX2TLR2 | |
| SCHEMBL6795717 | 0.85 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL608620 | 0.84 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL2625076 | 0.83 | KMT2A (0.58) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL16000763 | 0.83 | KMT2A (0.52) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL178787 | 0.83 | MDM4 (0.60) | KMT2ACASP3MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501499-B2 | Peptides derived from viral proteins for use as immunogens and dosage reactants | BIONOR IMMUNO AS (NO) | 2019-12-10 | — | — | US | disclosed |
| US-10124059-B2 | Dimeric scaffold peptides comprising HIV-1 GP120 and GP41 epitopes | BIONOR IMMUNO AS (NO) | 2018-11-13 | — | — | US | disclosed |
| EP-3338798-A1 | MULTIMERIC PEPTIDE | Bionor Immuno AS (NO) | 2018-06-27 | — | — | EP | disclosed |
| US-20160375129-A1 | DIMERIC SCAFFOLD PEPTIDES COMPRISING HIV-1 GP120 AND GP41 EPITOPES | BIONOR IMMUNO AS (NO) | 2016-12-29 | — | — | US | disclosed |
| US-9493514-B2 | Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes | BIONOR IMMUNO AS (NO) | 2016-11-15 | — | — | US | disclosed |
| US-20150152140-A1 | PEPTIDES DERIVED FROM VIRAL PROTEINS FOR USE AS IMMUNOGENS AND DOSAGE REACTANTS | BIONOR IMMUNO AS (NO) | 2015-06-04 | — | — | US | disclosed |
| EP-2859011-A1 | PEPTIDES DERIVED FROM VIRAL PROTEINS FOR USE AS IMMUNOGENS AND DOSAGE REACTANTS | Bionor Immuno AS (NO) | 2015-04-15 | — | — | EP | disclosed |
| US-20140044746-A1 | MONOMERIC AND MULTIMERIC IMMUNOGENIC PEPTIDES | BIONOR IMMUNO AS (NO) | 2014-02-13 | — | — | US | disclosed |
| WO-2013182661-A1 | PEPTIDES DERIVED FROM VIRAL PROTEINS FOR USE AS IMMUNOGENS AND DOSAGE REACTANTS | BIONOR IMMUNO AS (NO) | 2013-12-12 | — | — | WO | disclosed |
| EP-2661442-A1 | MONOMERIC AND MULTIMERIC IMMUNOGENIC PEPTIDES | Bionor Immuno AS (NO) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012092934-A1 | MONOMERIC AND MULTIMERIC IMMUNOGENIC PEPTIDES | BIONOR IMMUNO AS (NO) | 2012-07-12 | — | — | WO | disclosed |
| WO-2010023295-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-03-04 | — | — | WO | disclosed |
| US-5919523-A | Derivatization of solid supports and methods for oligomer synthesis | AFFYMETRIX, INC. (US) | 1999-07-06 | — | — | US | disclosed |
| US-5624711-A | AFFIXING FUNCTIONAL SITES TO THE SURFACE OF A SOLID SUBSTRATE | AFFYMAX TECHNOLOGIES, N.V. (NL) | 1997-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375129-A1 | DIMERIC SCAFFOLD PEPTIDES COMPRISING HIV-1 GP120 AND GP41 EPITOPES | CD4, HAVCR2, MAVS | KMT2A 4328/4885CASP3 2057/4885EPHX2 4456/4885 |
| US-10124059-B2 | Dimeric scaffold peptides comprising HIV-1 GP120 and GP41 epitopes | CD4, HAVCR2, MAVS | KMT2A 4328/4885CASP3 2057/4885EPHX2 4456/4885 |
| US-20140044746-A1 | MONOMERIC AND MULTIMERIC IMMUNOGENIC PEPTIDES | HLA-DRB1, CXCL10, CXCR3 | KMT2A 4712/4885CASP3 1217/4885EPHX2 4525/4885 |
| US-10501499-B2 | Peptides derived from viral proteins for use as immunogens and dosage reactants | HAVCR2, CXCL10, CCL5 | KMT2A 4395/4885CASP3 4245/4885EPHX2 4253/4885 |
| US-20150152140-A1 | PEPTIDES DERIVED FROM VIRAL PROTEINS FOR USE AS IMMUNOGENS AND DOSAGE REACTANTS | HAVCR2, CXCL10, CCL5 | KMT2A 4395/4885CASP3 4245/4885EPHX2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.